SkinHealth Systems Inc., formerly known as The Beauty Health Company, announced a corporate rebrand on April 22, 2026, with the new name taking effect immediately and appearing on the Nasdaq Capital Market by April 23. The change reflects a strategic pivot toward a clinically driven, science‑backed medical aesthetics platform, positioning the company to compete more aggressively in the medspa channel while leveraging its well‑known Hydrafacial flagship and expanding into complementary offerings such as SkinStylus microneedling and HydraScalp with Keravive™.
In its most recent quarterly results, the company reported a net loss of $8.1 million for Q4 2025, an improvement from a $10.3 million loss in Q4 2024. Revenue for the quarter was $82.4 million, down 1.3% from $83.7 million a year earlier, largely due to weaker delivery‑system sales. Gross margin rose to 64.4% from 62.7%, driven by a favorable mix shift toward higher‑margin consumables and lower inventory charges. Adjusted EBITDA reached $15.0 million, up from $9.0 million in Q4 2024, and the company guided for full‑year 2026 revenue of $285 million to $305 million and adjusted EBITDA of $35 million to $45 million— a slight decline in revenue outlook compared with the $300.8 million reported for 2025.
The company’s device sales have been a headwind, with delivery‑system revenue falling, while its consumables business has shown resilience. Gross margin expansion to 65.3% for 2025 from 54.5% in 2024 underscores the impact of the higher‑margin consumable mix. Management attributed the margin improvement to “strict cost controls” and a “favorable mix shift toward consumables.” The guidance for 2026 reflects a cautious outlook, with revenue expected to be slightly lower than 2025, but adjusted EBITDA projected to grow, indicating confidence in cost discipline and margin maintenance.
CEO Pedro Malha emphasized that the rebrand is “not simply a change in name. It represents a fundamental evolution in how we operate, and how we intend to compete.” He added that the company is “unlocking the full economic potential of our platform by strengthening commercial execution, expanding utilization, improving provider economics, and investing in clinically meaningful innovation.” These comments highlight the company’s focus on building a durable, scalable ecosystem of skin‑health technologies and solutions that deliver provider‑led outcomes.
The company’s global installed base exceeds 36,000 devices, and its business model relies on both device sales and recurring consumable revenue. While device sales have declined, the higher‑margin consumables segment has grown, supporting the company’s margin trajectory. The company is also navigating a class‑action lawsuit alleging undisclosed issues with its Syndeo devices, a legal challenge that could impact future device sales. Analysts have maintained a “Hold” rating, reflecting a mixed view of the company’s ability to sustain growth amid device sales headwinds and legal uncertainty.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.